Jump to the main content block

吳宗圃

吳宗圃(Chung-Pu Wu)

Appointment:  Professor

Lab:Cancer Biology Laboratory

Education:Ph.D.

University/Nation:University of Cambridge, UK

Tel: +886 3 2118800 (ext 3754)

E-mail : wuchung@mail.cgu.edu.tw

Research websitehttp://paulwea.wix.com/2014-06-13

Research interests:

Multidrug resistance (MDR) caused by the overexpression of ATP-binding cassette (ABC) drug transporter ABCB1 (MDR1, P-glycoprotein) and/or ABCG2 (BCRP, MXR) is a major obstacle to successful cancer chemotherapy. Functional ABCB1 or ABCG2 confers cross-resistance to multiple drugs of differing chemical classes by actively effluxing cytotoxic drugs out of cancer cells, significantly reducing the intracellular accumulation of these drugs and resulting in MDR. Moreover, ABCB1 and ABCG2 are highly expressed in various tissues including the intestine, liver, kidney, placenta, adrenal gland and blood-brain barrier (BBB), protecting the body from xenobiotics and harmful drugs. As a result, a majority of conventional chemotherapeutic agents are affected by the transport function of ABCB1 and/or ABCG2, such as reduced oral bioavailability, distribution and elimination of these drugs. Currently, the most effective way to re-sensitize MDR cancer cells is through direct and transient inhibition of the function and/or expression of these ABC drug transporters. However, the major obstacles with using novel compounds as clinically active inhibitors are often associated with the cost and the unforeseen intrinsic toxicity of these compounds. Therefore, we are proposing an alternative approach of repositioning (drug re-purposing) FDA approved therapeutic protein kinase inhibitors (PKIs) for the purpose of re-sensitizing MDR cancer cells and improve clinical outcome in patients with ABC transporter-positive MDR cancers in future clinical practices.

 Recent Publications (2018-2020)

  1. C-P Wu*, C-Y Hung, S Lusvarghi, et al.  Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cells.  Biochemical Pharmacology (2020) Jul; 180: 114137. (IF = 4.960; Journal Rank in PHARMACOLOGY & PHARMACY = 27/270) (*corresponding author)
  2. C-P Wu, T-H Hung, S-H Hsiao, et al.  Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.  Cancers (2020) 12(6), 1366. (IF = 6.126; Journal Rank in Oncology = 37/244)
  3. C-P Wu*, S Lusvarghi, S-H Hsiao, et al.  Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs.  Journal of Natural Products (2020) May 22;83(5):1461-1472. (IF = 3.779; Journal Rank in PLANT SCIENCES = 32/234) (*corresponding author)
  4. C-P Wu*, S-H Hsiao, Y-H Huang, et al.  Sitravatinib sensitizes ABCB1- and ABCG2-overexpressing multidrug resistant cancer cells to chemotherapeutic drugs.  Cancers (2020) Jan;12(1). pii: E195. (IF = 6.126; Journal Rank in Oncology = 37/244) (*corresponding author)
  5. C-P Wu*, S. Lusvarghi, P-J Tseng, et al.  MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs.  American Journal of Cancer Research (2020) Jan; 10(1):164-178. (IF = 5.177; Journal Rank in Oncology = 58/244) (*corresponding author)
  6. T-H Hung, S-Y Huang, S-F Chen, C-P Wu, and T-T Hsieh.  Decreased placental apoptosis and autophagy in pregnancies complicated by gestational diabetes with large-for-gestational age fetuses.  Placenta (2020) Jan;90: 27-36. (IF = 3.177; Journal Rank in OBSTETRICS & GYNECOLOGY =18/82)
  7. C-P Wu*, S. Lusvarghi, J-C Wang, et al.  The selective class Iia histone deacetylase inhibitor TMP195 resensitizes ABCB1- and ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic drugs.  International Journal of Molecular Sciences (2019) Dec;21(1). pii: E238. (IF = 4.556; Journal Rank in Biochemistry & Molecular Biology = 74/297) (*corresponding author)
  8. T-H Hung, S-F Chen, C-H Wu, and C-P Wu.  Increased soluble epoxide hydrolase in human gestational tissues from pregnancies complicated by acute chorioamnionitis.  Mediators of Inflammation (2019) Dec; 2019:8687120. (IF = 3.758; Journal Rank in IMMUNOLOGY = 63/158)
  9. C-P Wu*, S Lusvarghi, J-C Wang, et al.  Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.  Molecular Pharmaceutics (2019) Jul;16(7):3040-3052. (IF = 4.321; Journal Rank in PHARMACOLOGY & PHARMACY = 48/270) (*corresponding author)
  10. S-H Hsiao, S Lusvarghi, Y-H Huang, S. V. Ambudkar, S-C Hsu, and C-P Wu*.  The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug resistant cancer cells to conventional chemotherapeutic agents. Cancer Letters (2019) Mar; 445: 34-44. (IF = 7.360; Journal Rank in Oncology = 30/244) (*corresponding author)
  11. S-H Hsiao, M Murakami, N Yeh, Y-Q Li, T-H Hung, Y-S Wu g, S. V. Ambudkar and C-P Wu*.  The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines.  Cancer Letters (2018) Oct; 434: 81-90. (IF = 7.360; Journal Rank in Oncology = 30/244) (*corresponding author)
  12. C-P Wu*, M Murakami, S-H Hsiao, et al.  SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.  Cancer Letters (2018) Oct; 433: 259-272. (IF = 7.360; Journal Rank in Oncology = 30/244) (*corresponding author)
  13. C-P Wu*, Y-J Hsieh, M Murakami, et al.  Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.  Biochemical Pharmacology (2018) Sep; 155: 316-325. (IF = 4.960; Journal Rank in PHARMACOLOGY & PHARMACY = 27/270) (*corresponding author)
Click Num: